BR112016006153A2 - composição contendo polietileno glicol - Google Patents

composição contendo polietileno glicol

Info

Publication number
BR112016006153A2
BR112016006153A2 BR112016006153A BR112016006153A BR112016006153A2 BR 112016006153 A2 BR112016006153 A2 BR 112016006153A2 BR 112016006153 A BR112016006153 A BR 112016006153A BR 112016006153 A BR112016006153 A BR 112016006153A BR 112016006153 A2 BR112016006153 A2 BR 112016006153A2
Authority
BR
Brazil
Prior art keywords
polyethylene glycol
composition containing
containing polyethylene
salt
formula
Prior art date
Application number
BR112016006153A
Other languages
English (en)
Inventor
Yamada Kazuhito
Murai Kenji
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of BR112016006153A2 publication Critical patent/BR112016006153A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)

Abstract

resumo composição contendo polietileno glicol a presente invenção refere-se a uma composição farmacêutica compreendendo um composto representado pela fórmula (1) ou um sal dos mesmos e polietileno glicol.
BR112016006153A 2013-09-20 2014-09-18 composição contendo polietileno glicol BR112016006153A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013195329 2013-09-20
PCT/JP2014/074698 WO2015041294A1 (ja) 2013-09-20 2014-09-18 ポリエチレングリコール含有組成物

Publications (1)

Publication Number Publication Date
BR112016006153A2 true BR112016006153A2 (pt) 2017-08-01

Family

ID=52688941

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016006153A BR112016006153A2 (pt) 2013-09-20 2014-09-18 composição contendo polietileno glicol

Country Status (17)

Country Link
US (1) US20160228420A1 (pt)
EP (1) EP3047850A4 (pt)
JP (2) JP5856264B2 (pt)
KR (1) KR20160060656A (pt)
CN (1) CN105555271A (pt)
AU (1) AU2014322111A1 (pt)
BR (1) BR112016006153A2 (pt)
CA (1) CA2924628A1 (pt)
EA (1) EA201690621A1 (pt)
HK (2) HK1220632A1 (pt)
IL (1) IL244648A0 (pt)
MX (1) MX2016003566A (pt)
MY (1) MY163236A (pt)
PH (1) PH12016500461A1 (pt)
SG (1) SG11201602020QA (pt)
TW (1) TW201518291A (pt)
WO (1) WO2015041294A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987368B2 (en) 2015-03-17 2018-06-05 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition comprising polypeptide
EP3272362B1 (en) 2015-03-18 2023-12-13 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
JP2017008047A (ja) * 2015-06-25 2017-01-12 参天製薬株式会社 注射剤
CA2991015A1 (en) * 2015-07-01 2017-01-05 Santen Pharmaceutical Co., Ltd. Depot preparation containing citric acid ester
CN106902117A (zh) * 2015-12-23 2017-06-30 瑞阳(苏州)生物科技有限公司 一种预防或治疗脉络膜新生血管形成的药物
JP7018939B2 (ja) * 2016-09-26 2022-02-14 ルヤン （スーチョウ） バイオロジー サイエンス アンド テクノロジー カンパニー，リミテッド 眼疾患の治療のための組成物ならびに使用および調製方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA833692B (en) * 1982-05-28 1985-02-27 Beecham Group Plc Pharmaceutical formulations
JPS59101478A (ja) * 1982-11-29 1984-06-12 Sunstar Inc リグスチライドを安定に配合した水系組成物
JPH09110698A (ja) * 1995-10-19 1997-04-28 Taiho Yakuhin Kogyo Kk 経口用医薬組成物の製造法
ES2368153T3 (es) * 2004-02-17 2011-11-14 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que presenta un grupo 4-piridilalquiltio que presenta amino (no) sustituido introducido en el mismo.
JP4626353B2 (ja) * 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物
WO2005085201A1 (ja) * 2004-02-17 2005-09-15 Santen Pharmaceutical Co., Ltd. 置換又は無置換アミノ基を導入した４－ピリジルアルキルチオ基を有する新規環式化合物
US20060153920A1 (en) * 2004-09-24 2006-07-13 Ketan Amin Lyophilized pharmaceutical compositions
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
WO2007076358A1 (en) 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
JP2010534201A (ja) 2007-07-20 2010-11-04 アルコン，インコーポレイテッド 受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の目への送達のための医薬製剤
ES2693696T3 (es) * 2007-11-26 2018-12-13 Merial, Inc. Sistemas de disolventes para formulaciones de unción dorsal continua para combatir parásitos
CN105362221A (zh) 2009-03-03 2016-03-02 爱尔康研究有限公司 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
JP5662719B2 (ja) * 2009-07-17 2015-02-04 参天製薬株式会社 ２−［［［２−［（ヒドロキシアセチル）アミノ］−４−ピリジニル］メチル］チオ］−ｎ−［４−（トリフルオロメトキシ）フェニル］−３−ピリジンカルボキサミドのベンゼンスルホン酸塩、その結晶、その結晶多形およびそれらの製造方法
EP3158991B1 (en) * 2010-01-28 2021-03-17 Eagle Pharmaceuticals, Inc. Formulations of bendamustine

Also Published As

Publication number Publication date
PH12016500461A1 (en) 2016-05-16
MY163236A (en) 2017-08-30
JP5856264B2 (ja) 2016-02-09
IL244648A0 (en) 2016-04-21
CN105555271A (zh) 2016-05-04
TW201518291A (zh) 2015-05-16
WO2015041294A1 (ja) 2015-03-26
CA2924628A1 (en) 2015-03-26
JP2016094442A (ja) 2016-05-26
AU2014322111A1 (en) 2016-04-07
EA201690621A1 (ru) 2016-07-29
HK1221407A1 (zh) 2017-06-02
HK1220632A1 (zh) 2017-05-12
EP3047850A1 (en) 2016-07-27
US20160228420A1 (en) 2016-08-11
SG11201602020QA (en) 2016-04-28
EP3047850A4 (en) 2017-05-10
JP2015083565A (ja) 2015-04-30
MX2016003566A (es) 2016-06-02
KR20160060656A (ko) 2016-05-30

Similar Documents

Publication Publication Date Title
CY1122718T1 (el) Σκευασμα συνδυασμου δυο αντι-ιικων ενωσεων
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112015021983A8 (pt) compostos heterocíclicos, composições e usos dos mesmos
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
BR112014017749A8 (pt) Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
BR112016006153A2 (pt) composição contendo polietileno glicol
CO7111287A2 (es) Composiciones plaguicidas y procesos relacionados
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
BR112015022047A8 (pt) uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112013007362A2 (pt) composição farmacêutica
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20140134A (es) Composiciones farmacéuticas
BR112014025041B8 (pt) Composição farmacêutica
MA49116A (fr) Compositions pharmaceutiques contenant de l'insuline
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
AR095097A1 (es) Compuestos de fenoxietoxi
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201692270A1 (ru) Производные нафтиридиндиона
BR112015006270A2 (pt) composição de controle de peste e uso da mesma
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
EA201600394A1 (ru) Трициклические соединения пиперидина

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2532 DE 16-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.